EHMSG gratefully acknowledges the support of the following sponsors
RICHEN EUROPE is the European operating branch of the RICHEN GROUP, a major international group of medical device manufacturers with a global commitment. The company specializes in developing the best solutions for patients in the field of gastroenterology. Over the years our R&D department has excelled in the design and development of high-performance safe equipment and reagents for the diagnosis of Helicobacter pylori infection. Since 2015, the Richen Group has been supporting the European Helicobacter & Microbiota Study Group (EHMSG) as Platinum Sponsor. URL: https://www.richeneurope.eu/
TAKEDA is supporting the conference with an independent medical educational grant URL: www.takeda.com
Biocodex is a French family-owned pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745. Today, Biocodex focuses its business on three main areas: its “Microbiota Mission” by educating the general public and healthcare professionals on microbiota, by funding academic research in microbiota and providing solutions for preserving microbiota health; Orphan drugs for patients with severe orphan pathologies around the world, such as DIACOMIT®; Women’s health with the Saforelle brand for women of all ages. With 1,600 employees and 20 subsidiaries, Biocodex generated net revenues of €387 million in 2020. URL: https://www.biocodexmicrobiotainstitute.com/pro
BIOHIT OYJ is a Finnish biotechnology company operating on global markets. Our mission, “Innovating for Health”, describes our innovative products and services. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. BIOHIT is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the United Kingdom. Biohit’s series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare. URL: www.biohithealthcare.com | www.gastropanel.com
INFAI is specialized in the transfer of advanced analytical technology in the field of medical diagnostics and the development of innovative pharmaceutical products. The company is a pioneer in the use of stable isotopes and NMR in gastroenterology, cardiovascular and metabolic diseases.
INFAI's laboratories in Bochum, Germany are equipped with state-of-the-art NMR and IR-MS instruments. These facilities are used for internal research and product development, but are also available for collaborative and contract research. In recent years, a range of non-invasive, highly efficient breath tests using stable isotopes has been developed. One of these tests is already approved and available for routine diagnosis of Helicobacter pylori infections. Other tests used to determine gastric emptying rate and exocrine pancreatic insufficiency will be available soon.
Mayoly Spindler is an independent French family-run pharmaceutical company which has been growing for several decades thanks to effective and recognized pharmaceutical products.
We have extensive expertise in gastroenterology, rheumatology, ENT, general medicine and consumer health solutions. We have also diversified into dermocosmetics, with our Topicrem and Charlieu product lines. With our own production facilities, we are able to control our industrial developments.
Our business plan centres on the talent of our employees. We are a respectful and caring organization that values entrepreneurial spirit, pragmatism and responsibility.
All of us at Mayoly Spindler work together to grow our laboratories globally.
Phathom Pharmaceuticals is working to change the GI treatment landscape and improve the lives of patients with acid-related disorders.
Phathom is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years. URL: phathompharma.com
Meridian For more than 40 years, Meridian Bioscience has helped in early diagnosis and proper patient management by providing a line of trusted solutions so that patients can get back to living. At Meridian, we are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis.
We provide diagnostic solutions in areas including gastrointestinal, upper respiratory infections and pediatric testing. We have been pioneers in H. Pylori stool antigen testing and we continue to innovate and bring new solutions such as Curian® HpSA® recently.
Sercon are dedicated to the design, manufacture and support of Isotope Ratio Mass Spectrometers and their associated sample preparation systems. Our ABCA range of breath test instrumentation allows our customers to benefit from a range of solutions to meet their testing needs. We supply consumables of the highest quality for all our systems including the breath test kit for H.Pylori testing.